Loading organizations...

§ Private Profile · Bothell, WA 98011, USA
Clinical-stage biopharmaceutical company developing small-molecule therapeutics for neurodegenerative diseases, targeting HGF/MET system.
Athira Pharma has raised $86.4M across 2 funding rounds.
Key people at Athira Pharma.
Athira Pharma has raised $86.4M in total across 2 funding rounds.
Athira Pharma is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for neurodegenerative diseases, based in Bothell, Washington. The publicly traded firm focuses on modulating the hepatocyte growth factor and MET receptor pathways to restore neuronal health and treat conditions such as Alzheimer's, Parkinson's, and ALS. Operating with approximately 80 employees, the enterprise raised $204 million during its initial public offering on the NASDAQ exchange in September 2020. The company has received private and public financial backing from institutional investors including Perceptive Advisors, Dolby Family Ventures, and the Alzheimer's Drug Discovery Foundation. Under the current leadership of chief executive officer Mark Litton, the organization recently completed Phase 2/3 clinical trials for its primary drug candidate, fosgonimeton. Athira Pharma was originally founded under the name M3 Biotechnology in 2011 by Leen Kawas, Joseph Harding, and Jay Wright.
Athira Pharma has raised $86.4M in total across 2 funding rounds.
Athira Pharma's investors include Joseph Edelman, Richard Kayne, suzanne kayne, Avidity Partners, Franklin Templeton, Highside Capital Management, Janus Henderson Investors, LifeSci Venture Partners, Logos Capital, Rock Springs Capital, RTW Investments, Sahsen Ventures.
Key people at Athira Pharma.
Athira Pharma has raised $86.4M across 2 funding rounds. Most recently, it raised $85.0M Series B in June 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 4, 2020 | $85M Series B | Joseph Edelman | Richard Kayne, Suzanne Kayne, Avidity Partners, Franklin Templeton, Highside Capital Management, Janus Henderson Investors, Lifesci Venture Partners, Logos Capital, Rock Springs Capital, RTW Investments, Sahsen Ventures, Sofinnova Investments, Surveyor Capital, Venrock, Viking Global Investors | Announced |
| Apr 17, 2017 | $1.4M Venture Round | — | Howard Fillit, Dolby Family Ventures | Announced |
Athira Pharma is a clinical‑stage biopharmaceutical company developing small‑molecule therapeutics intended to *restore neuronal health* and slow neurodegeneration, with lead assets in late‑stage clinical study for Alzheimer’s disease and programs addressing other neurodegenerative and neuropsychiatric conditions[2][3].[6]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Biotech Landscape
Quick Take & Future Outlook
Sources used: company website and therapeutic pages[2][3][7], corporate hires/roles and program descriptions[4], historical and independent coverage including Nature and other summaries of Athira’s strategy and evolution[6][1].